{{Rsnum
|rsid=12334811
|Gene=PRKDC
|Chromosome=8
|position=47920417
|Orientation=plus
|GMAF=0.1717
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PRKDC
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 8.0 | 92.0
| HCB | 3.0 | 27.8 | 69.2
| JPT | 1.8 | 27.4 | 70.8
| YRI | 13.6 | 49.0 | 37.4
| ASW | 1.8 | 49.1 | 49.1
| CHB | 3.0 | 27.8 | 69.2
| CHD | 0.9 | 23.4 | 75.7
| GIH | 4.1 | 40.8 | 55.1
| LWK | 9.3 | 50.0 | 40.7
| MEX | 10.3 | 39.7 | 50.0
| MKK | 5.2 | 36.1 | 58.7
| TSI | 2.0 | 12.1 | 85.9
| HapMapRevision=28
}}{{PMID|18451257}} [[rs8178085]] and [[rs12334811]] with approaching dose-dependent effect on [[lung cancer]] predisposition, subjects carrying two to four risk genotypes were associated with a 43% decreased lung cancer risk compared with subjects carrying zero to one risk genotypes (adjusted odds ratio, 0.53; 95% confidence interval, 0.35-0.80).

[[rs228591]] variant allele or ataxia-telangiectasia and Rad3-related [[rs6782400]] wild-type homozygous genotype

{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}